At Harmonex Neuroscience Research, patients are given the opportunity to try new treatments for their conditions. Some of these treatments are already FDA approved and are currently being used by doctors. However, pharmaceutical companies may find that certain medications are more effective in a different population than intended. When this happens the companies will request that clinical trials be conducted.
Clinical trials (also known as clinical research) are research studies in human volunteers that investigate treatments and observe patient performance with new treatments. They play an important role in developing new treatment options for a variety of diseases.
Before any new treatment can be tested in humans, it must have shown positive results in the laboratory and/or in animal studies. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings.
The United States Food and Drug Administration (FDA) monitors most clinical trials to protect the participants and the general public. Ultimately, the FDA reviews and analyzes data from successful clinical trials to determine whether the experimental treatment should be approved for the treatment of a specific disease or disorder.
Clinical trials may be carried out using completely new treatment options or using treatments that are already available. Clinical trials are the safest and quickest way to confirm whether new treatments are truly beneficial for patients.
These treatment options and the doctor’s visits are free. Harmonex study patients receive the highest level of care available and are monitored and evaluated at greater levels than most patients.
Study patients typically receive full health screenings, extensive lab work and cardiovascular assessments, medications, and doctor’s visits; all at no cost to the patient.
Our research coordinators are fully trained in conducting and administering clinical trials. They have undergone extensive training in good clinical practice and thorough training in Harmonex Research standard operating procedures.
Harmonex is conducting a clinical trial for children with ADHD. Any male or female participants 4 to 5 years of age with ADHD are eligible to enroll in this study.
Harmonex is conducting a clinical trial for children with ADHD. Any male or female participants ages 4 to 5 years of age with ADHD are eligible for this study.
Harmonex is conducting a clinical trial for Autism. Any male or female participants ages 12 to 17 with Autism are eligible for this study.
Harmonex is conducting a clinical trial for adolescents with Bipolar (ages 10-17) and/or Schizophrenia (ages 13-17). Any male or female in this age group is eligible to enroll in this study.
Harmonex is conducting a clinical trial for ages 12 and older who have been diagnosed with Major Depressive Disorder (MDD), Post Traumatic Stress Disorder (PTSD), and/or Borderline Personality Disorder (BPD) are eligible for this study.
Harmonex is conducting a clinical trial for adults with bipolar disorder. Any individual ages 19 to 65 years of age with bipolar disorder is eligible to enroll in this study.
Harmonex is conducting a clinical trial for adults with Major Depression. Any male or female participants 19 to 65 years of age with Major Depression are eligible to enroll in this study.
Harmonex is conducting a clinical trial for Adults with Tourette’s Disorder. Individuals 18 or older with Tourette’s Disorder are eligible to enroll in this study.
Harmonex is conducting a clinical trial for children and adolescents with Irritability associated with Autism Disorder. Any male or female participants 5 to 17 years of age with Irritablity associated with Autistic Disorder are eligible to enroll in this study.
Harmonex is conducting a clinical trial for adults with Post Tramatic Stress Disorder. Any male or female participants ages 19 to 65 with PTSD are eligible to enroll in this study.
Harmonex is conducting a clinical trial for adults with Major Depression. Any male or female participants ages 22 to 64 with Major Depression are eligible for this study.